Potential role of cyclin‑dependent kinase 4/6 inhibitors in the treatment of mucosal melanoma  

作　　者：Chaoji Shi Houyu Ju Yunteng Wu Xuhui Ma Zhiyuan Zhang Guoxin Ren 

机构地区：[1]Department of Oral and Maxillofacial Head Neck Oncology,Shanghai Ninth People’s Hospital,College of Stomatology,Shanghai Jiao Tong University School of Medicine,Number 639,Zhi-Zao-Ju Road,Shanghai 200011,China [2]National Center for Stomatology,National Clinical Research Center for Oral Diseases,Shanghai 200011,China [3]Shanghai Key Laboratory of Stomatology,Shanghai Research Institute of Stomatology,Shanghai 200011,China [4]Research Unit of Oral and Maxillofacial Regenerative Medicine,Chinese Academy of Medical Sciences,Shanghai 200011,China

出　　处：《Holistic Integrative Oncology》2024年第1期462-475,共14页整合肿瘤学(英文)

基　　金：supported by the Shanghai Clinical Research Center for Oral Diseases(19MC1910600);CAMS Innovation Fund for Medical Sciences(CIFMS)(2019-I2M-5-037);Shanghai Clinical Research Center for Oral Diseases(19MC1910600);Shanghai’s Top Priority Research Center(2022ZZ01017);Fundamental research program funding of Ninth People’s Hospital affiliated to Shanghai Jiao Tong university School of Medicine(JYZZ187).

摘　　要：Mucosal melanoma(MM)is a rare and aggressive form of melanoma with a poorer prognosis compared to other subtypes.Recent large-scale next-generation sequencing studies,including our own research,have demonstrated that the molecular characteristics and potential oncogenic drivers of MM differ significantly from those of cutaneous melanoma.The emergence of selective CDK4/6 inhibitors,already approved for use in breast cancer and undergo-ing phase III clinical trials for other solid tumors,represents a promising development in the treatment of MM.Recent studies have shown that CDK4/6 inhibitors not only induce cell cycle arrest but also play a crucial role in facilitating the interaction between tumor cells and the host immune system.Moreover,our findings indicate that dysregulation of cell cycle progression due to cyclin‐dependent kinase 4(CDK4)amplification is a significant genetic characteris-tic in a substantial portion of MM cases.Targeting CDK4 in specific MM patients shows promise for precision cancer therapy,utilizing molecularly characterized MM patient-derived xenograft(PDX)models and clinical trials.This paper provides an overview of existing literature on CDK4/6 dysregulation in MM,as well as preclinical and clinical investiga-tions on CDK4/6 inhibitors and potential combination therapies for MM treatment.

关 键 词：Mucosal melanoma CDK4/6 inhibitors Cyclin-dependent kinases Clinical trial IMMUNOTHERAPY 

分 类 号：R73[医药卫生—肿瘤]